Frequent methylation of DAB2, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 214 (2) , 314-317
Abstract
No abstract availableKeywords
Funding Information
- Department of Pharmaceutical Biochemistry and the Faculty of Pharmacy, Poznan University of Medical Sciences in Poznań, Poland
This publication has 19 references indexed in Scilit:
- The negative regulators of Wnt pathway—DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survivalTumor Biology, 2014
- Frequent hypermethylation of WNT pathway genes in laryngeal squamous cell carcinomasJournal of Oral Pathology & Medicine, 2014
- miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancerOncogene, 2013
- Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancersInternational Journal of Oncology, 2013
- The molecular pathogenesis of head and neck squamous cell carcinomaJournal of Clinical Investigation, 2012
- Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosaOral Oncology, 2011
- Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoterJournal of Clinical Investigation, 2010
- Putative tumour-suppressor gene DAB2is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinomaBMC Cancer, 2010
- Dab2 stabilizes Axin and attenuates Wnt/β-catenin signaling by preventing protein phosphatase 1 (PP1)–Axin interactionsOncogene, 2009
- The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through AxinOncogene, 2007